ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen Says Recent Sensipar Study Failed to Meet Primary Endpoint

By Mia Lamar Amgen Inc. (AMGN) said Friday that a study evaluating its Sensipar drug for effectiveness in reducing the risk of mortality and cardiovascular events in patients suffering from chronic kidney disease failed to meet its primary endpoint. Sensipar--which is marketed as Mimpara in Europe--was first approved in 2004 to treat thyroid problems in patients with kidney disease and cancer. The company recorded $808 million in global sales of the drug last year. Amgen said Friday it undertook the Phase 3 trial of Sensipar to discover whether the drug could positively impact the high rates of mortality and incidences like heart failure experienced by patients with chronic kidney disease that are receiving dialysis. Results, however, were not statistically significant, Amgen said. The company noted analyses from the study are ongoing and will be submitted for presentation at a major medical meeting later this year. Amgen, the biggest stand-alone biotechnology company, has been pursuing deals to bolster its research-and-development pipeline as sales growth slows for older drugs. Shares were recently off 26 cents to $68.84. Write to Mia Lamar at mia.lamar@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
02/11/201619:01:00New Drug Treatment Kyprolis® ▼ (carfilzomib) for Relapsed Mu...
02/10/201613:38:31Amended Statement of Ownership (sc 13g/a)
02/10/201610:17:35Amended Statement of Ownership (sc 13g/a)
02/09/201618:20:00Panel Recommends FDA Approval of Remicade Knockoff
02/09/201618:16:00Panel Recommends FDA Approval of Remicade Knockoff
02/07/201618:15:00Drug Industry Launches Ad Campaign Aimed at Lawmakers
02/05/201617:06:00Amgen To Present At The Leerink Partners 5th Annual Global Healthcare...
02/04/201616:17:00Phase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint...
02/04/201616:00:00Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3...
01/28/201616:40:00Amgen Profit Rises 39%; 2016 Outlook Raised
01/28/201616:31:00Amgen Profit Rises 39%; 2016 Outlook Raised
01/28/201616:00:00Amgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And...
01/25/201617:20:00FDA Accepts Amgen's Biosimilar Biologics License Application...
01/25/201616:03:00Amgen Announces Webcast of 2015 Fourth Quarter and Full Year...
01/23/201613:00:00Vectibix® (panitumumab) And Best Supportive Care Improves Overall...
01/22/201601:00:00Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor...
01/21/201616:32:00FDA Approves New Kyprolis® (Carfilzomib) Combination Therapy...
01/11/201612:50:00Celgene Names New CEO, Cuts 2015 Profit Outlook
01/10/201620:33:00Drugmakers Keep Raising Prices Despite Criticisms
01/07/201616:05:00Amgen To Present At The 34th Annual J.P. Morgan Healthcare Conference

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad